ArticleMedical microbiology and immunology2025
Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis.
Article in Medical microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Mitochondrial Localization and Abundance of Leishmania Cytochrome c Oxidase Subunit IV Is Maintained Following Loss of Mitochondrial Membrane Potential Associated With Mammalian Temperature.Molecular microbiology · 2026Article
- In Silico Design and Evaluation of TcGAPDH as a Vaccine Against Chagas Disease: A Reverse Vaccinology Approach.Acta parasitologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
American tegumentary leishmaniasis (ATL) is a neglected tropical disease that affects millions of people worldwide, for which no effective vaccine or optimal treatment is currently available. In this study, we evaluated the effectiveness of Leishmania recombinant antigens selected through a seroproteomic approach using a murine model. Two Leishmania (Viannia) braziliensis antigens, identified as human anti-Leishmania IgG2-reactive but IgG3 non-reactive, markers subtypes for Th1 and Th2 responses respectively, were selected for immunization of BALB/c mice formulated with Quil-A® (QA) adjuvant. Vaccine efficacy was assessed based on lesion size, parasite burden, levels of IFN-γ and IL-10, delayed-type hypersensitivity (DTH) response, and antibody production against both recombinant and crude Leishmania antigens. Pyruvate kinase (PK) and mitochondrial processing protease (MPP) were identified. Both antigens combined with QA significantly reduce the parasite load and lesion size. The group immunized with the combination MPP+PK+QA, which used lower concentrations of each antigen, showed a greater reduction in parasite burden compared to the single-antigen groups (MPP+QA and PK+QA). Quil-A® enhanced the immunogenicity of rPK, as indicated by increased IFN-γ levels. Additionally, rPK induced IL-10 production at levels comparable to the control group. Both PK+QA and MPP+PK+QA elicited a significant DTH response after Leishmania challenge. Most vaccinated groups exhibited an early immune response to whole Leishmania antigens, with a Th1-biased profile observed in the PK+QA and MPP+PK+QA groups. These findings offer valuable insights into antigen selection based on antibody subclass profiling and identify two novel vaccine candidates with potential for the development of effective vaccines against ATL.
Indexed as
Identifiers
40900277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.